Monoclonal Ig deposition disease (MIDD) is a broad and uncommon entity, including light chain deposition disease (LCDD), light-and heavy-chain deposition disease and heavychain deposition disease. 1 Overall, the kidney is the major target organ, the clinical picture being most frequently characterised by nephrotic syndrome, hypertension and renal failure. 2 Light-chain Fanconi syndrome due to proximal tubular involvement may also occur, and typically manifests with type II renal tubular acidosis, hypophosphatemia, glycosuria and hypouricemia. Heart, liver and other organs are less frequently involved. 3, 4 In approximately one-third of patients with MIDD the underlying clone of monoclonal plasma cells cannot be routinely detected. 2 However, recent availability of serum free light chain (FLC) assay has allowed to demonstration of the presence of increased monoclonal FLC in virtually all patients. 5 Treatment strategies in these patients have been highly variable, ranging from steroids with or without chemotherapy 2 to high-dose therapy followed by autologous stem-cell transplantation (ASCT). 5, 6 We retrospectively analyzed the outcomes of 8 consecutive patients who were admitted to our Institute from 1993 to 2006 and received a diagnosis of MIDD, as confirmed by kidney biopsy. Additional investigations to confirm the diagnosis included light microscopy, congo red staining, immunofluorescence with anti-k and anti-l antibodies and EM; immunohistochemistry with antibodies directed against plasma cell-associated Ags was performed, when appropriate.
Patient characteristics are shown in Table 1 . All patients but one had a concomitant diagnosis of multiple myeloma (MM). Five patients had baseline glomerular filtration rate (GFR) levels less than 50 mL/min and two of these were dialysisdependent.
Induction therapy before ASCT included conventional chemotherapy with VCR, adriamycin and dexamethasone, VAD, in three patients, and high-dose dexamethasone with or without thalidomide (100 mg daily) in the remaining four patients. Following induction, PBSC collection (median number of collected CD34 þ cells: 6.45 Â 10 6 /kg, range 3.4 --11.7) was performed using G-CSF alone, 15 mcg/kg, in four patients in whom the GFR was less than 30 mL/min, or intermediate-dose CY followed by G-CSF in the remaining four patients who had a GFR exceeding 30 mL/min.
Seven patients received a single or double (two patients) ASCT up-front; in the last patient, ASCT was performed at the time of relapse, 7 years after the diagnosis, due to adverse events occurring after CTX. According to GFR values, the dose of melphalan varied between 140 and 200 mg/m 2 , with a single patient receiving 100 mg/m 2 ( Table 1) . G-CSF, 5 mcg/kg, was given to all patients, starting 6 days after ASCT.
Assessment of hematological response was performed 3 months after ASCT, according to the European Group for Blood and Marrow Transplant criteria; 7 amyloidosis criteria were used in the single patient with a diagnosis of MGUS, and to evaluate renal response in patients who were dialysis-independent at the time of diagnosis. 8 ASCT was generally well tolerated; no additional toxicity was observed in the two patients who were dialysis-dependent. Median time to hematological recovery (neutrophils above 500/mm 3 and platelets above 20 000/mm 3 ) was 11 days (range 10 --12).
Five patients achieved a CR, one patient a PR, whereas in one patient disease progression (PD) was observed. The single patient who received a diagnosis of MGUS and melphalan 100 mg/m 2 was considered to be in stable disease.
With a median follow-up of 59 (range 26 --144) months all patients are alive and no patient was lost at follow-up. At the cutoff date of January 2011, four patients remained in CR after a median of 136 (range 58 --144) months. In one patient, a biological relapse from CR, in the absence of organ damage, was observed at 6 months after ASCT; the patient is currently out of therapy, 38 months after relapse. No signs of disease progression were observed after 60 and 26 months in the two patients who achieved a PR and stable disease, respectively. The patient with PD became dialysis-dependent 30 months after ASCT. The single patient who received ASCT as salvage therapy, achieved a CR, but subsequently developed progressive worsening of renal function and became dialysis-dependent 2 years after ASCT.
Six patients were evaluable for renal response. Of these, two (including a patient with Fanconi syndrome) who achieved a CR and PR showed a decrease in renal proteinuria of 71% and 60%, respectively, at 3 months after ASCT, while an additional patient had a renal response after 44 months. It is worth noting that organ improvement due to MIDD can occur late, up to 2 years after ASCT. 9 One of the responding patients, with a concomitant diagnosis of diabetes, lately experienced a progressive increase of proteinuria. A second kidney biopsy showed that the renal damage was secondary to diabetes, while an improvement of LCDD was documented.
A renal allograft was performed after 2 and 8 years from ASCT in the two patients who where dialysis-dependent and achieved a CR. No recurrence of renal impairment was observed at 1 and 4 years.
Results of the present analysis, although related to a small number of patients, extend and support the value of ASCT in the treatment of MIDD. Six patients out of 8 achieved a CR or PR, which was maintained for a median of 136 (range 6 --144) months. Achievement of a durable hematological response was associated with a renal improvement. In accordance with previous reports, two patients with CR and end-stage renal failure received a renal allograft, with long-term maintenance of a normal renal function.
The optimal treatment strategy for patients with MIDD still has to be determined and may be further improved by the use of novel agents. 10 However ASCT remains a safe and effective option. 
